<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340961</url>
  </required_header>
  <id_info>
    <org_study_id>DFD-29-CD-002</org_study_id>
    <nct_id>NCT03340961</nct_id>
  </id_info>
  <brief_title>A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical assessments of efficacy will be conducted based on Investigator's Global Assessment
      (IGA, modified scale without erythema), Clinician's Erythema Assessment (CEA), and on
      inflammatory lesion counts at Weeks 4, 8, 12 and 16 in comparison to Baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundred (200) male and female subjects with papulopustular rosacea will be enrolled to
      get 176 completed subjects (forty-four (44) completers each in groups 1 to 4).

      After assessing eligibility during an up to 28 days screening period, 200 subjects will be
      enrolled in the study (fifty subjects each in groups 1 to 4). Subject visits are scheduled at
      Screening, Baseline (Day 1), and Weeks 4, 8, 12 and 16.

      Clinical assessments of efficacy will be conducted based on Investigator's Global Assessment
      (IGA, modified scale without erythema), Clinician's Erythema Assessment (CEA), and on
      inflammatory lesion counts at Weeks 4, 8, 12 and 16 in comparison to Baseline. Additionally,
      high sensitivity C-reactive protein (hs-CRP) in the blood will be assessed at Baseline, and
      at Week 16 to explore any impact of the treatment on the inflammatory pathology.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">November 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Each subject will be allocated to one of the following treatment groups, receiving 1 capsule once daily in the morning for 16 weeks:
DFD-29 Extended Release Capsules (40 mg)
DFD-29 Extended Release Capsules (20 mg)
Doxycycline Modified Release Hard Capsules (40 mg)
Placebo Capsules</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe</measure>
    <time_frame>16 weeks</time_frame>
    <description>Proportion of subjects with Investigator Global Assessment (IGA) 'treatment success' - Grade 0 or 1 at the end of study with at least 2 grade reduction from Baseline to Week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Inflammatory Lesion Count Reduction</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The total inflammatory lesion count is carried out by visual inspection by the Investigator at every study visit from Screening up to Week 16 (or at early termination). Inflammatory lesions will be recorded on a diagram of a human face, divided in 4 quadrants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Change in RosaQoL (Rosacea Quality of Life) Score From Baseline to Week 16</measure>
    <time_frame>Median change in the score from Baseline to Week 16</time_frame>
    <description>The RosaQoL assessment is carried out by the Investigator using the validated RosaQoL questionnaire, at every study visit from Screening up to Week 16 (or at early termination). The RosaQol tool has 21 questions related to the impact that Rosacea has on various dimensions influencing quality of life. Each question is graded from 1 (Never) - 5 (All the time), thus leading to a minimum score of 21 (21 x 1) to a maximum score of 105 (21 x 5) per subject at every visit. Higher the score, poorer is the quality of life. This outcome measured the change in the score from Baseline to Week 16.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>DFD-29 Extended Release Capsules (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFD-29 Extended Release Capsules (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oraycea® (doxycycline) Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsules once per day for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD-29 Extended Release Capsules (40 mg)</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>DFD-29 Extended Release Capsules (40 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD-29 Extended Release Capsules (20 mg)</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>DFD-29 Extended Release Capsules (20 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraycea® (doxycycline) Capsules</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>Oraycea® (doxycycline) Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsules</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>Placebo Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be able to understand the requirements of the study and be willing to
             give written informed consent.

          2. Male and female subjects aged 18 years and above.

          3. Subjects, any gender or ethnicity (and of Fitzpatrick skin type I - III), must be in
             good general health as determined by the Investigator.

          4. Subjects must have a clinical diagnosis of papulopustular rosacea, IGA grade 2 - 4.

          5. Subjects must have 10 - 40 (both inclusive) inflammatory lesions (papules and
             pustules) of rosacea over the face.

          6. Subjects must have not more than 2 nodules.

          7. Subjects with moderate to severe erythema with a total score of 5 - 20 on the CEA
             scale.

          8. Females must have a negative urine pregnancy test at the screening and baseline visit.

          9. Females must either be postmenopausal with no menses for at least 12 months or
             surgically sterile (hysterectomy or tubal ligation) or agree to use a highly effective
             method of contraception with a pearl index of &lt;1% up to 1 month after last dose.

         10. Subjects must be in good general health as determined by the investigator and
             supported by the medical history and normal or not clinically significant abnormal
             vital signs (blood pressure and pulse).

        Exclusion Criteria:

          1. Females who are pregnant or nursing or planning to become pregnant during the study.

          2. Male whose female partner is planning to conceive a child.

          3. Subjects who have been treated for rosacea within the 30 days prior to the Baseline
             Visit (e.g. metronidazole, azelaic acid, doxycycline or brimonidine).

          4. Subjects who have been treated with systemic retinoids within 6 months prior to the
             Baseline visit.

          5. Subjects who have participated in a trial involving any investigational product in the
             90 days prior to the Baseline Visit.

          6. Subjects with any disease or medical condition that would interfere with the study
             outcome or place the subject at undue risk.

          7. Subjects who use or have used systemic steroids within the 30 days prior to the
             Baseline Visit or any other immunosuppressive medication.

          8. Subjects who are on anti-coagulants or those who are likely to require anti-coagulants
             during the study period.

          9. History of drug or alcohol abuse in the last year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Sidgiddi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director-Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Bad Bentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 09</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Buxtehude</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Dülmen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 08</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Mahlow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Pommelsbrunn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <results_first_submitted>March 24, 2020</results_first_submitted>
  <results_first_submitted_qc>April 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2020</results_first_posted>
  <last_update_submitted>April 11, 2020</last_update_submitted>
  <last_update_submitted_qc>April 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03340961/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03340961/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DFD-29 Extended Release Capsules (40 mg)</title>
          <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (40 mg): Oral Treatment</description>
        </group>
        <group group_id="P2">
          <title>DFD-29 Extended Release Capsules (20 mg)</title>
          <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (20 mg): Oral Treatment</description>
        </group>
        <group group_id="P3">
          <title>Oraycea® (Doxycycline) Capsules</title>
          <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
Oraycea® (doxycycline) Capsules: Oral Treatment</description>
        </group>
        <group group_id="P4">
          <title>Placebo Capsules</title>
          <description>Placebo Capsules once per day for 16 weeks.
Placebo Capsules: Oral Treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of prohibited treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>rongful enrollment (I/E criteria not me</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject developed an exclusion criterion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The FAS (full analysis set) had all subjects who had at least one post Baseline efficacy assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>DFD-29 Extended Release Capsules (40 mg)</title>
          <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (40 mg): Oral Treatment</description>
        </group>
        <group group_id="B2">
          <title>DFD-29 Extended Release Capsules (20 mg)</title>
          <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (20 mg): Oral Treatment</description>
        </group>
        <group group_id="B3">
          <title>Oraycea® (Doxycycline) Capsules</title>
          <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
Oraycea® (doxycycline) Capsules: Oral Treatment</description>
        </group>
        <group group_id="B4">
          <title>Placebo Capsules</title>
          <description>Placebo Capsules once per day for 16 weeks.
Placebo Capsules: Oral Treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="15.05"/>
                    <measurement group_id="B2" value="51.1" spread="13.13"/>
                    <measurement group_id="B3" value="51.6" spread="12.94"/>
                    <measurement group_id="B4" value="52.5" spread="12.92"/>
                    <measurement group_id="B5" value="50.5" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe</title>
        <description>Proportion of subjects with Investigator Global Assessment (IGA) 'treatment success' - Grade 0 or 1 at the end of study with at least 2 grade reduction from Baseline to Week 16.</description>
        <time_frame>16 weeks</time_frame>
        <population>The FAS (full analysis set) included all subjects that had at least one post Baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-29 Extended Release Capsules (40 mg)</title>
            <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (40 mg): Oral Treatment</description>
          </group>
          <group group_id="O2">
            <title>DFD-29 Extended Release Capsules (20 mg)</title>
            <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (20 mg): Oral Treatment</description>
          </group>
          <group group_id="O3">
            <title>Oraycea® (Doxycycline) Capsules</title>
            <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
Oraycea® (doxycycline) Capsules: Oral Treatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>Placebo Capsules once per day for 16 weeks.
Placebo Capsules: Oral Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe</title>
          <description>Proportion of subjects with Investigator Global Assessment (IGA) 'treatment success' - Grade 0 or 1 at the end of study with at least 2 grade reduction from Baseline to Week 16.</description>
          <population>The FAS (full analysis set) included all subjects that had at least one post Baseline efficacy assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Inflammatory Lesion Count Reduction</title>
        <description>The total inflammatory lesion count is carried out by visual inspection by the Investigator at every study visit from Screening up to Week 16 (or at early termination). Inflammatory lesions will be recorded on a diagram of a human face, divided in 4 quadrants.</description>
        <time_frame>16 Weeks</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-29 Extended Release Capsules (40 mg)</title>
            <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (40 mg): Oral Treatment</description>
          </group>
          <group group_id="O2">
            <title>DFD-29 Extended Release Capsules (20 mg)</title>
            <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (20 mg): Oral Treatment</description>
          </group>
          <group group_id="O3">
            <title>Oraycea® (Doxycycline) Capsules</title>
            <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
Oraycea® (doxycycline) Capsules: Oral Treatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>Placebo Capsules once per day for 16 weeks.
Placebo Capsules: Oral Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Total Inflammatory Lesion Count Reduction</title>
          <description>The total inflammatory lesion count is carried out by visual inspection by the Investigator at every study visit from Screening up to Week 16 (or at early termination). Inflammatory lesions will be recorded on a diagram of a human face, divided in 4 quadrants.</description>
          <population>FAS population</population>
          <units>Count of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" spread="9.72"/>
                    <measurement group_id="O2" value="-12.6" spread="12.92"/>
                    <measurement group_id="O3" value="-10.5" spread="15.18"/>
                    <measurement group_id="O4" value="-7.3" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in RosaQoL (Rosacea Quality of Life) Score From Baseline to Week 16</title>
        <description>The RosaQoL assessment is carried out by the Investigator using the validated RosaQoL questionnaire, at every study visit from Screening up to Week 16 (or at early termination). The RosaQol tool has 21 questions related to the impact that Rosacea has on various dimensions influencing quality of life. Each question is graded from 1 (Never) - 5 (All the time), thus leading to a minimum score of 21 (21 x 1) to a maximum score of 105 (21 x 5) per subject at every visit. Higher the score, poorer is the quality of life. This outcome measured the change in the score from Baseline to Week 16.</description>
        <time_frame>Median change in the score from Baseline to Week 16</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-29 Extended Release Capsules (40 mg)</title>
            <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (40 mg): Oral Treatment</description>
          </group>
          <group group_id="O2">
            <title>DFD-29 Extended Release Capsules (20 mg)</title>
            <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (20 mg): Oral Treatment</description>
          </group>
          <group group_id="O3">
            <title>Oraycea® (Doxycycline) Capsules</title>
            <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
Oraycea® (doxycycline) Capsules: Oral Treatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>Placebo Capsules once per day for 16 weeks.
Placebo Capsules: Oral Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in RosaQoL (Rosacea Quality of Life) Score From Baseline to Week 16</title>
          <description>The RosaQoL assessment is carried out by the Investigator using the validated RosaQoL questionnaire, at every study visit from Screening up to Week 16 (or at early termination). The RosaQol tool has 21 questions related to the impact that Rosacea has on various dimensions influencing quality of life. Each question is graded from 1 (Never) - 5 (All the time), thus leading to a minimum score of 21 (21 x 1) to a maximum score of 105 (21 x 5) per subject at every visit. Higher the score, poorer is the quality of life. This outcome measured the change in the score from Baseline to Week 16.</description>
          <population>FAS Population</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" lower_limit="-53" upper_limit="11"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-34" upper_limit="8"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-30" upper_limit="25"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-37" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from subjects from the time of signing of the ICF up to Week 16/End of Study Visit.</time_frame>
      <desc>Adverse events were collected by spontaneous reports from subjects, either verbal or recorded in the subject’s diary, by directed question of subjects, and by observation. All AEs from the time of signing of the ICF up to the EOS visit were recorded.
AEs occurring from the time of first study drug administration up to the End-of-Study were defined as treatment emergent AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>DFD-29 Extended Release Capsules (40 mg)</title>
          <description>DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (40 mg): Oral Treatment</description>
        </group>
        <group group_id="E2">
          <title>DFD-29 Extended Release Capsules (20 mg)</title>
          <description>DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
DFD-29 Extended Release Capsules (20 mg): Oral Treatment</description>
        </group>
        <group group_id="E3">
          <title>Oraycea® (Doxycycline) Capsules</title>
          <description>Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
Oraycea® (doxycycline) Capsules: Oral Treatment</description>
        </group>
        <group group_id="E4">
          <title>Placebo Capsules</title>
          <description>Placebo Capsules once per day for 16 weeks.
Placebo Capsules: Oral Treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Coronary artery disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Atrial fibrillation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <description>Retinal detachment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <description>Lymphoma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloma</sub_title>
                <description>Papilloma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" events="9" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="47" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E2" events="35" subjects_affected="14" subjects_at_risk="48"/>
                <counts group_id="E3" events="37" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E4" events="29" subjects_affected="13" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Srinivas Sidgiddi, Senior Director</name_or_title>
      <organization>Dr. Reddy's Lab, INC</organization>
      <phone>908-458-5362</phone>
      <email>Srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

